EUVIMEDEUVIMED entdecken
Klinische Studie

Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure

Maryam AlKhatry, Babusai Rapaka, Daniel B Maselli, Donna Maria Abboud iD, Vitor O Brunaldi iD, Tala Mahmoud, Rabih Ghazi, Farah Abdul Razzak, Khushboo Gala, Imad Joudah, Fedaa Housen, Sana Al Qadi und 3 weitere

Endoscopy · 01.11.2023 · 55 (11) · 1028-1034

DOI: 10.1055/a-2117-6274 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Endoscopy, erschienen am 01.11.2023. Verfasst von Maryam AlKhatry und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Insulin Resistance. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: UAE Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity.

Methods

Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety.

Results

42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not (P < 0.001 for POSE 2.0; P = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events.

Conclusion

POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseInsulin ResistanceAdultHumansObesityLife StyleLiver

Autor:innen und Institutionen

  • Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
  • Gastroenterology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil.

ORCID-Profile: Donna Maria Abboud, Vitor O Brunaldi, Eric J Vargas, Andrew C Storm

Förderung

  • UAE Ministry of Health

Zitieren

APA

AlKhatry, M., Rapaka, B., Maselli, D. B., Abboud, D. M., Brunaldi, V. O., Mahmoud, T., Ghazi, R., Abdul Razzak, F., Gala, K., Joudah, I., Housen, F., Al Qadi, S., Vargas, E. J., Storm, A. C., & Abu Dayyeh, B. K. (2023). Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure. Endoscopy, 55(11), 1028-1034. https://doi.org/10.1055/a-2117-6274

Vancouver

AlKhatry M, Rapaka B, Maselli DB, Abboud DM, Brunaldi VO, Mahmoud T, et al. Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure. Endoscopy. 2023;55(11):1028-1034. doi:10.1055/a-2117-6274

BibTeX
@article{AlKhatry2023,
  author = {AlKhatry, Maryam and Rapaka, Babusai and Maselli, Daniel B and Abboud, Donna Maria and Brunaldi, Vitor O and Mahmoud, Tala and Ghazi, Rabih and Abdul Razzak, Farah and Gala, Khushboo and Joudah, Imad and Housen, Fedaa and Al Qadi, Sana and Vargas, Eric J and Storm, Andrew C and Abu Dayyeh, Barham K},
  title = {Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure},
  journal = {Endoscopy},
  year = {2023},
  volume = {55},
  number = {11},
  pages = {1028--1034},
  doi = {10.1055/a-2117-6274}
}
Kostenlos starten →